{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:37:52Z","timestamp":1789699072774,"version":"4.0.1"},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Interleukin (IL)-10 expressing CD19 chimeric antigen receptor (CAR) T cells (META 10-19) have demonstrated encouraging clinical activity in B-cell acute lymphoblastic leukemia, but their safety and efficacy in relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) remain unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the safety and efficacy of META 10-19 in patients with R\/R DLBCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This nonrandomized, phase 1 clinical trial was conducted at the First Affiliated Hospital of Zhejiang University School of Medicine. Patients were enrolled from November 16, 2023, to April 7, 2025. The data cutoff date was January 20, 2026. The data analysis was conducted on January 22, 2026. Twenty patients were screened, and 13 received a META 10-19 infusion. The median duration of follow-up was 15.6 (range, 0.7-25.5) months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>\n                      Following lymphodepletion with fludarabine and cyclophosphamide, patients received META 10-19 at dose levels of 2\u2009\u00d7\u200910\n                      <jats:sup>3<\/jats:sup>\n                      , 5\u2009\u00d7\u200910\n                      <jats:sup>3<\/jats:sup>\n                      or 2\u2009\u00d7\u200910\n                      <jats:sup>4<\/jats:sup>\n                      CAR T cells\/kg.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary end points were adverse events, dose-limiting toxic effects, and objective response rate. The secondary end points included complete remission (CR) and a cellular kinetic of META 10-19.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 13 treated patients (median age, 61 years [range, 35-74 years]; 8 men [61.5%] and 5 women [38.5%]), the objective response rate was 92.3%, including CR in 11 patients (84.6%) and partial remission in 1 patient (7.7%). One patient died before response assessment because of disease-related gastrointestinal complications. Cytokine release syndrome occurred for 12 patients (grade 1: n\u2009=\u20098; grade 2: n\u2009=\u20093; grade 3: n\u2009=\u20091), and immune effector cell\u2013associated neurotoxicity syndrome occurred for 2 patients (grade 1: n\u2009=\u20091; grade 2: n\u2009=\u20091). Robust in vivo CAR T-cell expansion was observed across dose levels, with a median (range) peak expansion of 660.7 (30.7-10\u202f562.3) cells\/\u00b5L. At data cutoff, 5 patients experienced a maintained CR and 7 experienced disease relapses or progression (2 with CD19 negative relapses).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The results of this nonrandomized clinical trial suggest that ultralow-dose META 10-19 demonstrated promising antitumor activity and a manageable safety profile in patients with R\/R DLBCL. Further investigation in larger cohorts is warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT06120166?term=NCT06120166&amp;amp;amp;viewType=Card&amp;amp;amp;rank=1\">NCT06120166<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2026.2490","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:30:22Z","timestamp":1784820622000},"page":"1003","source":"Crossref","is-referenced-by-count":1,"title":["Ultralow-Dose Interleukin 10\u2013Expressing Chimeric Antigen Receptor T Cells in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma"],"prefix":"10.1001","volume":"12","author":[{"given":"Yongxian","family":"Hu","sequence":"first","affiliation":[{"name":"Bone Marrow Transplantation Center of the First Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"},{"name":"Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China"},{"name":"Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Zhang","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center of the First Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"},{"name":"Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China"},{"name":"Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Gao","sequence":"additional","affiliation":[{"name":"Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Zheijiang, China"},{"name":"State Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yetian","family":"Dong","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center of the First Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"},{"name":"Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China"},{"name":"Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Fu","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center of the First Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"},{"name":"Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China"},{"name":"Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiling","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Zheijiang, China"},{"name":"State Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunuo","family":"Zhu","sequence":"additional","affiliation":[{"name":"Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Zheijiang, China"},{"name":"State Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Feng","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center of the First Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"},{"name":"Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China"},{"name":"Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruimin","family":"Hong","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center of the First Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"},{"name":"Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China"},{"name":"Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Wei","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center of the First Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"},{"name":"Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China"},{"name":"Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duoduo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center of the First Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"},{"name":"Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China"},{"name":"Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhen","family":"Cui","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center of the First Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"},{"name":"Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China"},{"name":"Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simao","family":"Huang","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center of the First Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"},{"name":"Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China"},{"name":"Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinging","family":"Yang","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center of the First Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"},{"name":"Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China"},{"name":"Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daojun","family":"Bai","sequence":"additional","affiliation":[{"name":"Leman Biotech Co, Ltd, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoyun","family":"Cheng","sequence":"additional","affiliation":[{"name":"Leman Biotech Co, Ltd, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbin","family":"Cui","sequence":"additional","affiliation":[{"name":"Leman Biotech Co, Ltd, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Ren","sequence":"additional","affiliation":[{"name":"Leman Biotech Co, Ltd, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongling","family":"Liu","sequence":"additional","affiliation":[{"name":"Leman Biotech Co, Ltd, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youjia","family":"Li","sequence":"additional","affiliation":[{"name":"Leman Biotech Co, Ltd, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Chen","sequence":"additional","affiliation":[{"name":"Leman Biotech Co, Ltd, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Zhou","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou, China"},{"name":"Innovation Institute for Artificial Intelligence in Medicine and MOE Engineering Research Center of Innovative Anticancer Drugs, Zhejiang University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongrui","family":"Wang","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center of the First Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"},{"name":"Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China"},{"name":"Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugang","family":"Guo","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center of the First Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"},{"name":"Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Zheijiang, China"},{"name":"State Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou, China"},{"name":"Leman Biotech Co, Ltd, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Tang","sequence":"additional","affiliation":[{"name":"Institute of Bioengineering, \u00c9cole Polytechnique F\u00e9d\u00e9rale de Lausanne, Lausanne, Switzerland"},{"name":"Institute of Materials Science and Engineering, \u00c9cole Polytechnique F\u00e9d\u00e9rale de Lausanne, Lausanne, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingbing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Centre for Leading Medicine and Advanced Technologies of IHM, First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China"},{"name":"National Key Laboratory of Immune Response and Immunotherapy, University of Science and Technology of China, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center of the First Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"},{"name":"Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China"},{"name":"Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"26","key":"coi260038r1","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma.","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"coi260038r2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma.","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10254","key":"coi260038r3","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"coi260038r4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1146\/annurev-immunol-090222-110914","article-title":"T cell exhaustion.","volume":"42","author":"Baessler","year":"2024","journal-title":"Annu Rev Immunol"},{"key":"coi260038r5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-med-012017-043208","article-title":"CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions.","volume":"69","author":"Hashimoto","year":"2018","journal-title":"Annu Rev Med"},{"issue":"5","key":"coi260038r6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"6","key":"coi260038r7","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41590-021-00940-2","article-title":"Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity.","volume":"22","author":"Guo","year":"2021","journal-title":"Nat Immunol"},{"issue":"11","key":"coi260038r8","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases.","volume":"42","author":"Zhao","year":"2024","journal-title":"Nat Biotechnol"},{"issue":"11","key":"coi260038r9","doi-asserted-by":"publisher","first-page":"e898","DOI":"10.1016\/S2352-3026(25)00253-4","article-title":"IL-10\u2013expressing, anti-CD19 CAR T cells for patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: an open-label, single-arm, phase 1 study.","volume":"12","author":"Xu","year":"2025","journal-title":"Lancet Haematol"},{"issue":"6","key":"coi260038r10","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3324\/haematol.2024.286027","article-title":"Immune effector cell-associated hematotoxicity: mechanisms, clinical manifestations, and management strategies.","volume":"110","author":"Beyar-Katz","year":"2025","journal-title":"Haematologica"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2851990\/jamaoncology_hu_2026_oi_260038_1789560619.95073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:01:02Z","timestamp":1789657262000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2851990"}},"subtitle":["A Nonrandomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2026.2490","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}